Several studies reported high levels of SOX2 expression in glioblastoma multiforme (GBM; WHO IV) than in the low-grade gliomas (LGGs) (Annovazzi et al., 2011; Guo et al., 2011; Vasquez et al., 2017). This evidence concerns the gene SOX2 and central nervous system cancer.